Department / Division
Neurology / Neurology Chair
Durham, NC 27710
Movement disorders; Parkinson's disease and other Parkinsonian disorders; generalized and focal dystonias; Lewy body disease; myoclonus; restless legs syndrome; progressive supranuclear palsy; corticobasal ganglionic degeneration; multiple-system atrophy; Shy-Drager syndrome; spasmodic torticollis; tremor and tic disorders; botulinum toxin injections; deep-brain stimulation
Mark Stacy has clinical trial efforts concentrated on Neuroprotective and Neuro-regenerative therapies in PD, and developing biomarkers for early diagnosis in PD. He has extensive experience with Glial Derived Neurotrophic Factor (GDNF), neuroimmunophyllins (GPI-1046, AMG-474), jnk inhibitors (CEP-1347, TCH-346), and viral vectors (Ceregene). His independent research interests in Parkinson’s disease include motor and non-motor symptoms of wearing off, and pathological gambling and other impulse control disorders. He has published more than 100 manuscripts in the areas of PD, dystonia, tremor and other movement disorders. He is also the editor of The Handbook of Dystonia.
This faculty member has no reported relationships with industry.